KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC)

被引：13
|
作者：
Schmid, P.
Park, Y. H.
Munoz-Couselo, E.
Kim, S-B
Sohn, J.
Im, S-A
Holgado, E.
Foukakis, T.
Kuemmel, S.
Dent, R.
Yin, L.
Ding, Y.
Tryfonidis, K.
Cortes, J.
机构：
[1] Barts Canc Inst, Ctr Med Expt, London, England
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Yonsei Univ, Coll Med, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Seoul, South Korea
[7] Ramon y Cajal Univ Hosp, Madrid, Spain
[8] Karolinska Univ Hosp, Radiumhemmet, Stockholm, Sweden
[9] Kliniken Essen Mitte, Essen, Germany
[10] Natl Canc Ctr, Singapore, Singapore
[11] Merck & Co Inc, Kenilworth, NJ USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-PD5-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD5-01
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab (pembro) plus chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173
    Schmid, Peter
    Park, Yeon Hee
    Munoz-Couselo, Eva
    Kim, Sung-Bae
    Sohn, Joohyuk
    Im, Seock-Ah
    Holgado, Esther
    Wang, Yang
    Dang, Thao
    Aktan, Gursel
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
    Schmid, P.
    Salgado, R.
    Park, Y. H.
    Munoz-Couselo, E.
    Kim, S. B.
    Sohn, J.
    Im, S. -A.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Yin, L.
    Wang, A.
    Tryfonidis, K.
    Karantza, V.
    Cortes, J.
    Loi, S.
    ANNALS OF ONCOLOGY, 2020, 31 (05) : 569 - 581
  • [3] Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro) plus chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial
    Loi, S.
    Schmid, P.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] EFFECTS OF PEMBROLIZUMAB ON THE TUMOR MICROENVIRONMENT (TME) AFTER ONE PRESURGERY TREATMENT CYCLE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (TNBC): PHASE 1B KEYNOTE-173 STUDY
    Schmid, Peter
    Park, Yeon Hee
    Munoz-Couselo, Eva
    Kim, Sung-Bae
    Sohn, Joohyuk
    Im, Seock-Ah
    Holgado, Esther
    Foukakis, Theodoros
    Kuemmel, Sherko
    Dent, Rebecca
    Sun, Yuan
    Huang, Lingkang
    Yearley, Jennifer
    Jelinic, Petar
    Karantza, Vassiliki
    Cortes, Javier
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A364 - A364
  • [5] Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro) plus chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial
    Loi, S.
    Schmid, P.
    Cortes, J.
    ark, Y. H.
    Munoz-Couselo, E.
    Kim, S-B
    Sohn, J.
    Im, S-A
    Holgado, E.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Wang, A.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [6] Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
    Dent, Rebecca
    Cortes, Javier
    Park, Yeon Hee
    Munoz-Couselo, Eva
    Kim, Sung-Bae
    Sohn, Joohyuk
    Im, Seock-Ah
    Holgado, Esther
    Foukakis, Theodoros
    Kuemmel, Sherko
    Yearley, Jennifer
    Wang, Anran
    Nebozhyn, Michael
    Huang, Lingkang
    Cristescu, Razvan
    Jelinic, Petar
    Karantza, Vassiliki
    Schmid, Peter
    BREAST CANCER RESEARCH, 2025, 27 (01)
  • [7] KEYNOTE-522: Phase III study of pembrolizumab (pembro) 1 chemotherapy (chemo) vs placebo 1 chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)
    Schmid, P.
    Cortes Castan, J.
    Bergh, J.
    Pusztai, L.
    Denkert, C.
    Verma, S.
    McArthur, H. L.
    Zhao, J.
    Aktan, G.
    Dang, T.
    Dent, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
    Schmid, P.
    Cortes, J.
    Dent, R.
    Pusztai, L.
    McArthur, H. L.
    Kuemmel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Fasching, P. A.
    Cardoso, F.
    Jia, L.
    Karantza, V.
    Zhao, J.
    Aktan, G.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 853 - 854
  • [9] KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)
    Dent, R.
    Cortes, J.
    Pusztai, L.
    McArthur, H. L.
    Kuemmel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Fasching, P. A.
    Cardoso, F.
    Jia, L.
    Jensen, E.
    Karantza, V.
    Aktan, G.
    O'Shaughnessy, J.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1241 - S1242
  • [10] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
    Schmid, Peter
    Cortes, Javier
    Bergh, Jonas C. S.
    Pusztai, Lajos
    Denkert, Carsten
    Verma, Sunil
    McArthur, Heather L.
    Kummel, Sherko
    Ding, Yu
    Karantza, Vassiliki
    Dang, Thao
    Dent, Rebecca Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345